CrowdStrike CEO: AI security threats are a long-term positive; do not rush to judge short-term performance impacts
- Chief Executive Officer George Kurtz stated that concerns about AI-driven cybersecurity threats are increasingly benefiting the company, but it is too early for investors to expect this impact to be reflected in first-quarter results. He explained that the widely discussed Mythos incident occurred in mid-April, while the company's fiscal quarter ended at the end of April, and enterprise software requires time to deploy, so the effects would not be immediately seen in the financials.
- Although CrowdStrike’s latest financial report exceeded expectations and the full-year outlook was raised, the company’s stock still fell 4% because some investors questioned why the Mythos incident did not more significantly boost recent results. Kurtz emphasized that the raised performance guidance is the more meaningful signal—the company increased its full-year net new annual recurring revenue forecast by more than $50 million, reflecting strong confidence in customer demand.
- Kurtz noted that enterprises want to deploy more AI securely, which is driving accelerated demand for the company’s AI security products. In the second quarter, the sales pipeline for its AI detection and response platform surpassed $50 million, up 250% quarter-over-quarter. He refuted the notion that “AI advances will reduce the need for cybersecurity vendors,” arguing that AI actually makes attackers stronger, thereby increasing the need for comprehensive security platforms—a favorable tailwind for CrowdStrike.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Most panda coin types from the 2026 edition steadily rebounded in August
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage
Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.
2-Yr Benchmark Govt Yields - Germany vs Other Nations
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
